We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

69 hedge funds and large institutions have $60.1M invested in Ocular Therapeutix in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 73 → 69 (-4)

7.74% less ownership

Funds ownership: 53.62% → 45.88% (-7.7%)

13% less call options, than puts

Call options by funds: $378K | Put options by funds: $434K

17% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 23

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

38% less capital invested

Capital invested by funds: $96.5M → $60.1M (-$36.4M)

Holders
69
Holders Change
-4
Holders Change %
-5.48%
% of All Funds
1.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
19
Reduced
23
Closed
15
Calls
$378K
Puts
$434K
Net Calls
-$56K
Net Calls Change
-$188K

Top Buyers

Rank Fund Capital Flow
1
HP
Hikari Power
Japan
+$409K
2
VF
Virtu Financial
New York
+$322K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$214K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$196K
5
Deutsche Bank
Deutsche Bank
Germany
+$153K

Top Sellers

Rank Fund Capital Flow
1
CCI
Columbus Circle Investors
-$6.63M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.56M
3
CS
Credit Suisse
Switzerland
-$1.07M
4
B
Bailard
California
-$907K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$599K
Name Holding Trade Value Shares
Change 		Change in
Stake
VVM
1
Versant Venture Management
California
$9.86M – – –
Jennison Associates
2
Jennison Associates
New York
$8.88M +$103K +20,132 +1%
SHI
3
SV Health Investors
Massachusetts
$7.14M – – –
BlackRock
4
BlackRock
New York
$6.31M +$57.7K +11,293 +0.8%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$5.55M -$346K -67,737 -5%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$5.18M -$599K -117,300 -9%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.77M +$214K +41,960 +4%
State Street
8
State Street
Massachusetts
$1.56M +$1.33K +261 +0.1%
Northern Trust
9
Northern Trust
Illinois
$1.16M -$4.43K -868 -0.3%
Morgan Stanley
10
Morgan Stanley
New York
$1.15M -$58K -11,363 -4%
DAM
11
Deltec Asset Management
New York
$953K -$488K -95,468 -31%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$783K -$60.7K -11,888 -6%
NA
13
Nottingham Advisors
New York
$654K +$12.8K +2,500 +2%
BCM
14
Bridgeway Capital Management
Texas
$460K – – –
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$371K -$412K -80,678 -49%
HP
16
Hikari Power
Japan
$356K +$409K +80,011 New
Bank of New York Mellon
17
Bank of New York Mellon
New York
$309K -$62.7K -12,267 -15%
Wells Fargo
18
Wells Fargo
California
$296K -$42.9K -8,402 -11%
VF
19
Virtu Financial
New York
$280K +$322K +63,020 New
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$267K +$14.9K +2,911 +5%
TCIM
21
TIAA CREF Investment Management
New York
$233K -$17.2K -3,368 -6%
Deutsche Bank
22
Deutsche Bank
Germany
$221K +$153K +29,938 +149%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$219K +$196K +38,405 +356%
NA
24
NewEdge Advisors
Louisiana
$200K -$15.3K -3,000 -7%
AllianceBernstein
25
AllianceBernstein
Tennessee
$198K +$13.8K +2,700 +6%
1
2 3 4

OCUL Hedge Fund Activity: Q4 2017 in Review

69 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2017, worth a combined $60.1M — down 38% from $96.5M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of OCUL and 11 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 19 added.

The largest buyer was Hikari Power, opening a new position worth an estimated $409K. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $6.63M sold.

  • 69 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2017, down from 73 in Q3 2017.
  • Funds reported $60.1M of Ocular Therapeutix stock for Q4 2017, down 38% quarter-over-quarter.
  • 11 funds opened new Ocular Therapeutix positions in Q4 2017 and 15 closed out, a net change of -4 holders.
  • The largest Ocular Therapeutix buyer in Q4 2017 was Hikari Power, an estimated $409K added.
  • The largest Ocular Therapeutix seller in Q4 2017 was Columbus Circle Investors, an estimated $6.63M sold.

Based on aggregated 13F filings for Q4 2017.